The life sciences company BTG is developing a pill that will supposedly treat obstuctive sleep apnea:
BGC20-0166 is a novel combination of two marketed serotonin modulating drugs being developed for the treatment of OSA.
Various sertonergic and serotenergic/noradrenergic antidepressants, including Prozac and protriptyline, have been used to treat OSA. These medications have a mild effect on osa. They slightly improve osa by increasing upper airway tone and also possibly by decreasing REM sleep. The effects are mild and antidepressants are not considered to be an effective treatment for OSA.
I don't recommend buying stock in BTG.